Eli Lilly and Company last month filed an NDA for its new ADHD treatment, atomoxetine. The drug will be the first nonstimulant treatment available for ADHD, if approved. The compound appears to be well tolerated in company-sponsored clinical trials, and its efficacy is roughly equivalent to standard stimulant treatments. The new drug is a potent inhibitor of norepinephrine reuptake. Common side effects associated with the drug are headache, abdominal pain, nausea and vomiting, anorexia and weight loss, nervousness, somnolence, and insomnia. In a head-to-head comparison of atomoxetine and methylphenidate, a significantly higher percentage of patients taking atomoxetine experienced vomiting and somnolence than did patients taking methylphenidate.